IDWeek2015

Preventing - and Planning for - the Next Influenza Pandemic

By October 11, 2015

Influenza surveillance and response remains an ongoing, and changing, challenge-and pandemic preparedness goes well beyond stockpiling vaccines, noted speakers at IDWeek 2015's closing plenary session.

Long-term Testosterone Replacement Ups Risk of Cardiovascular Events, Death in HIV+ Men

By October 11, 2015

Long-term testosterone replacement therapy (TRT) is associated with an increased risk of cardiovascular events (CVE) and death among HIV-positive men, authors of a retrospective chart review reported at IDWeek 2015.

Less Treatment Failures Seen With Empiric Cephalexin in Pediatric UTI

By October 11, 2015

For treatment of uncomplicated, outpatient urinary tract infection (UTI), fewer failures were seen with empiric cephalexin than with trimethoprim/sulfamethoxazole (TMP-SMX) or amoxicillin, researchers presented at IDWeek 2015.

Some Pediatric Cellulitis Successfully Treated at Home, Study Suggests

By October 11, 2015

Children with uncomplicated cellulitis may be safely treated at home, as they are unlikely to have bacteremia, Laila F. Ibrahim, MBBChBAO, from the Royal Children's Hospital @ Home Department in Parkville, Australia, reported at IDWeek 2015.

Ceftolozane/Tazobactam May Be New Tx Option for Complicated Pyelonephritis

By October 11, 2015

The combination of ceftolozane and tazobactam showed comparable outcomes to levofloxacin in the treatment of complicated pyelonephritis, according to results from the Phase 3 ASEPCT-cUTI trial presented at IDWeek 2015.

Linezolid, Vancomycin Compared for MRSA Pneumonia

By October 11, 2015

There was no statistically significant difference in clinical outcomes between patients with methicillin-resistant Staphylococcus aureus (MRSA) pneumonia who were treated with linezolid and those treated with vancomycin except mortality, reported ManShan Celica Tong, PharmD, MPH, from Medical University of South Carolina, Charleston, SC, at IDWeek 2015.

Factors Identified in Tenofovir-Associated Renal Failure Risk

By October 11, 2015

Among HIV-positive patients, hepatitis C virus (HCV) coinfection, low baseline CD4 counts and other factors increase the risk of tenofovir-associated renal failure, reported authors of a retrospective cohort study presented at IDWeek 2015.

Early Childhood Vaccination Drives Down Consolidated Pneumonia Rates

By October 11, 2015

Introduction of early childhood immunization with the pneumococcal conjugate PCV13 vaccine has rapidly reduced the incidence of pediatric consolidated pneumonia (CP) cases in Argentina, according to findings from a prospective single-municipality population-based study reported at IDWeek 2015.

Fluoroquinolones Linked to More Than Tendon Ruptures

By October 11, 2015

Treatment with fluoroquinolones was definitely associated with subsequent tendon ruptures, and was found to be a possible contributor in aortic aneurysms, presented Nick Daneman, MD, MSc, from the University of Toronto, Ontario, Canada, at IDWeek 2015.

Why HIV/TB Coinfected Patients Are Discontinuing Tx at Alarming Rates

By October 11, 2015

Patients with HIV and tuberculosis (TB) coinfection are discontinuing first-line antitubercular therapy (ATT) at disturbingly high rates because of side effects like skin reactions, gastrointestinal symptoms, and hepatotoxicity, according to study findings reported at IDWeek 2015.

Pertussis Vaccination for Neonates an Effective Option to Maternal Vaccination

By October 11, 2015

Neonatal acellular pertussis vaccination may be a safe alternative to maternal immunization, according to efficacy data presented at IDWeek 2015.

Increased Mortality With Tigecycline as Adjunct Tx for Severe CDAD

By October 11, 2015

Tigecycline used as adjunctive therapy for severe Clostridium difficile-associated diarrhea (CDAD) led to higher rates of colectomy and higher mortality, according to results of a multicenter study presented by Candace Marr, DO, from the Catholic Health System and The State University of New York at Buffalo, Buffalo, NY, at IDWeek 2015.

Providers Urged to Recommend This Vaccine for HIV-Positive Patients

By October 10, 2015

Due to several potential barriers, the rates of completion for the human papillomavirus (HPV) vaccine series are lower among HIV-positive patients and men at Denver Health, a large urban public healthcare system, researchers reported at IDWeek 2015.

TAF and TDF Compared for Kidney, Bone Toxicity in Black HIV+ Patients

By October 10, 2015

Including tenofovir alafenamide (TAF) in single-tablet elvitegravir/cobicistat/emtricitabine (E/C/F/TAF) is associated with reduced renal and bone toxicity compared to tenofovir disoproxil fumarate (TDF)-containing single-tablet (E/C/F/TDF) therapy, according to an analysis of data from two Phase 3 trials, reported at IDWeek 2015.

RV5 Vaccine Safe, Immunogenic in HIV-Positive/HEU Infants

By October 10, 2015

Attenuated live rotavirus vaccine (RV5) appears to be safe and immunogenic among HIV-positive and HIV-exposed but uninfected (HEU) infants, according to findings from the randomized, double-blind, Phase 2 IMPAACT P1072 study reported at IDWeek 2015.

Dual Therapy Could Reduce SSI Incidence By 63%

By October 10, 2015

Dual therapy with vancomycin plus a beta-lactam antibiotic may reduce surgical site infections (SSI) by up to 63%, a study presented at IDWeek 2015 has found, with the strongest association seen in cardiac procedures.

<i>Lactobacillus</i> Bacteremia Rare in Pediatric ICU, Despite Probiotic Use

By October 10, 2015

Even though probiotics are frequently administered in pediatric intensive care units (ICUs), incidence of probiotic-associated bacteremia appears to be low, authors of a single-institution case-control study reported at IDWeek 2015.

Anti-HCV Combo Shows Comparable Efficacy for HIV Co-Infection, Mono-Infection

By October 10, 2015

Researchers at IDWeek 2015 presented positive efficacy data for the grazoprevir/elbasvir (EBR/GZR) regimen for patients co-infected with hepatitis C virus (HCV) and HIV.

Ledipasvir/Sofosbuvir Effective in HCV Mono- and HCV/HIV Coinfected Patients

By October 10, 2015

Once-daily single-tablet ledipasvir/sofosbuvir (LDV/SOF) provided high rates of sustained virologic response (SVR) at Week 12 in both patients with hepatitis C virus (HCV) mono-infection and HIV/HCV coinfection, according to results of a pooled analysis presented at IDWeek 2015.

Antibiotic Prophylaxis Intervention Slashes NICU MRSA Rates

By October 10, 2015

Monthly intranasal mupirocin prophylaxis in the neonatal intensive care unit (NICU) dramatically decreased healthcare-associated transmission of methicillin-resistant Staphylococcus aureus (MRSA) infections by 43% and cut invasive staphylococcal infections by 73%, according to a study presented at IDWeek 2015.

Probiotic Intervention May Reduce CDI Rates in Antibiotic Recipients

By October 10, 2015

Administering a three-Lactobacillus spp. probiotic to patients undergoing antibiotic therapy might reduce the frequency of nosocomial Clostridium difficile infections (CDI), suggest findings from a single-institution study reported at IDWeek 2015.

Renal Status Not a Factor for Tedizolid, Linezolid Efficacy in ABSSSI

By October 10, 2015

Renal impairment does not appear to affect the safety or clinical efficacy of tedizolid compared to linezolid among adults treated for skin and skin structure infections (ABSSSI), according to a post-hoc analysis of data from two randomized, controlled phase 3 clinical trials, reported at IDWeek 2015.

Inappropriate Empirical Antimicrobial Tx May Lengthen Hospitalization

By October 10, 2015

Patients with good prognoses suffer longer hospitalizations when they receive inappropriate empirical antimicrobial therapy for E. coli and other gram-negative bloodstream infections, according to study findings reported at IDWeek 2015.

Are <i>C. diff</i> Cure Rates Better With High Dose Vancomycin?

By October 10, 2015

High-dose oral vancomycin does not improve clinical outcomes over 125mg low dose vancomycin therapy among adult patients with nosocomial Clostridium difficile infection (CDI), according to retrospective study findings reported at IDWeek 2015

Opioid Use Ups Hospitalization Risk for Serious Infection in Older Adults

By October 10, 2015

Opioid use was associated with an increased risk of hospitalizations for serious infections, and was higher with current use at higher daily doses and when using long-acting formulations, data from a case series analysis has shown at IDWeek 2015.

SVR12 Rates Higher in Treatment-Naïve, Noncirrhotic Patients with HCV/HIV

By October 09, 2015

Treatment with boceprevir and pegylated interferon/ribavirin (PIFN/R) in persons co-infected with hepatitis C virus (HCV)and HIV resulted in higher sustained virologic response (SVR) rates at 12 weeks if they were treatment-naïve without cirrhosis, Phase 3 trial results reported at IDWeek 2015 have found.

ATV+c or ATV+r With FTC/TDF: Effective Options for All Patients with HIV?

By October 09, 2015

The combination of either atazanavir plus cobicistat (ATV+c) or atazanavir plus ritonavir (ATV+r) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) is an effective treatment option for patients who are infected with HIV regardless of race, sex, and age, with high and similar virologic success rates, a Week 48 subgroup analysis of a randomized Phase 3 trial confirmed at IDWeek 2015.

Concurrent 3-Vaccine Administration Can Cover 5 Serogroups in Meningococcal Disease

By October 09, 2015

The bivalent rLP2086 meningococcal serogroup B vaccine coadministered with MCV4 and Tdap met noninferiority immunogenicity criteria without a clinically significant increase in reactogenicity, a study representing the first report of concomitant adolescent vaccination of all three vaccines concluded at IDWeek 2015.

Study Urges Adding Routine Probiotic Prophylaxis for ELBW Infants

By October 09, 2015

Adding routine probiotic prophylaxis in neonatal intensive care units (NICUs) is protective against necrotizing enterocolitis and bloodstream infections among extremely low birth weight (ELBW) infants, and improves their survival rates following necrotizing enterocolitis, according to authors of a multicenter quasi-experimental study in Germany.

Investigational IV Delafloxacin Effective in Obese Patients with ABSSSI

By October 09, 2015

Delafloxacin (DLX), an investigational broad-spectrum fluoroquinolone antibiotic, may offer an alternative treatment to vancomycin/aztreonam (VAN) in obese patients with acute bacterial skin and skin structure infections (ABSSSI), reported authors of a Phase 3 trial presented at IDWeek 2015.